2Sullivan,Mcelroy AD,Honsinger RW et al. Treating community-acquired pheumonia with one-daily getifloxacin vs one-daily levofloxacin[J]. J Respir Dis,1999,20 (Suppl):49～59.
3Medeiros E A.Treatmen of aduts with community-acquired respiratory tract infections:results of a multicentrlc clinical trial with gatifloxacin[J].Braz J Infect Dis,2002,6(4):149.
4Anzueto A,Gotfried M,Wikler M A,et al.Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbation of chronic bronchitis[J].Clin Ther,2002,24(6):906.
5Owens R C Jr,Ambrose P G.Clinical use of the fluoroquinolones[J].Med Clin North.Am,2000,84 (6):1 447.
6Rubinstein E.History of quinolones and their side effects[J].Chemotherapy,2001,47(Suppl3):44.
7Gajjar D A,La Creata F P,Llderman H D,et al,A doseescalation study of the safety,tolerability,amd pharmacokinetics of intravenous gatiflozacin in healthy adult men[J].Pharmacotherapy,2000,20(6):49.
8Hosaka M,Kinoshita S,Toyama A,et al.Antibacterial properties of AM-1155,a new 8-methoxy quinolone[J].J Antimicrob Chemother,1995,36:293.
9Tomioka H,Saito H,Satok.Comparative antimycobacterial activities of the newly synthesixed quinolone AM-1 155,sparfloxacin and oflxacin[J].Antimicrob Agents Chemother,1993,37(6):1 259.
